SEC Form 4 · accession 0001209191-18-035943
KYNTRA BIO, INC. · KYNB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Pat Cotroneo
Officer — SVP, Finance and CFO
Period of report
Jun 1, 2018
Accepted (ET)
Jun 5, 2018 · 7:40 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000921299
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 1, 2018 | F | 993 | $54.05 | D | 230,311 | D | |
| Common Stock | Jun 4, 2018 | M | 6,013 | $19.39 | A | 236,324 | D | |
| Common StockF2,F3 | Jun 4, 2018 | S | 6,013 | $55.16 | D | 230,311 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $19.39 | Jun 4, 2018 | M | 6,013 | D | — | Feb 22, 2026 | Common Stock | 6,013 | 32,000 | D |
Explanation of responses
- F1Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units.
- F2Shares sold pursuant to a 10b5-1 plan.
- F3The shares were sold at prices ranging from $55.00 to $55.38. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in equal amounts quarterly thereafter for the following three years.